Skip to main content
TipRanks
Go Ultimate75% OFF

Tanvex Biopharma (TANVF) Stock Price & Analysis

6 Followers

TANVF Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
$221.18M
Enterprise Value
$12.13B
Total Cash (Recent Filing)
$592.56M
Total Debt (Recent Filing)
$2.08B
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Mar 10, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

The sharp 2025 revenue increase indicates meaningful commercial expansion and improving market traction. If the growth is sustained, it can provide greater operating scale, support investment in development and market access, and strengthen the company’s ability to build a broader biologics business.

Improved Leverage

The substantial reduction in debt-to-equity improves financial flexibility relative with prior years and lowers balance-sheet pressure. Increased equity and total assets also provide a stronger capital base, giving Tanvex more room to pursue development and commercialization while managing its funding needs.

Biosimilar Business Focus

A focused biosimilar strategy addresses established biologic therapies while targeting affordability, creating a structurally relevant commercial opportunity. Tanvex’s combination of research, clinical development, manufacturing preparation, and market access activities supports an integrated pathway from product development toward commercialization.

Bears Say

Persistent Operating Losses

Persistent operating and net losses show that the business has not yet reached earnings stability despite strong revenue growth. Continued losses can constrain reinvestment, weaken shareholder returns, and make future performance dependent on achieving much better operating leverage and cost control.

Negative Cash Generation

Sustained negative operating and free cash flow means current activities consume rather than generate capital. This limits financial resilience and reduces the funds available for clinical development, manufacturing preparation, and commercialization, leaving improvement in cash conversion as a major requirement for durable growth.

Continued Funding Dependence

Even with improved leverage, ongoing operating deficits leave Tanvex reliant on external funding until performance improves. That dependence can restrict strategic flexibility, increase execution pressure, and make the company more vulnerable to financing requirements while it advances its biologic and biosimilar pipeline.

TANVF FAQ

What is Tanvex Biopharma’s market cap?
Tanvex Biopharma’s market cap is $221.18M.
When is Tanvex Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tanvex Biopharma’s earnings last quarter?
Tanvex Biopharma released its earnings results on Nov 11, 2026. The company reported -$0.046 earnings per share for the quarter.
Is Tanvex Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Tanvex Biopharma pay dividends?
Tanvex Biopharma does not currently pay dividends.
What is Tanvex Biopharma’s EPS estimate?
Tanvex Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tanvex Biopharma have?
Tanvex Biopharma has 265,224,370 shares outstanding.
What happened to Tanvex Biopharma’s price movement after its last earnings report?
Tanvex Biopharma reported an EPS of -$0.046 in its last earnings report. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Tanvex Biopharma?
Currently, no hedge funds are holding shares in TANVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology